Physician profile
Amelia Ng
NPI 1982717526
$5,614.36
in general payments reported to CMS, 2019-2025
25 companies · $1,300 in 2025
The $1,300 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $235 · 2020: $688 · 2021: $720 · 2022: $1,010 · 2023: $861 · 2024: $801 · 2025: $1,300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,961.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,961.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,707.78 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $688.07 | 2019-2025 | Breztri, Airsupra, Fasenra |
| Actelion Pharmaceuticals US, INC. | $582.02 | 2019-2025 | Opsumit, Uptravi |
| Mylan Specialty L.P. | $473.07 | 2020-2024 | Yupelri |
| Shionogi INC | $472.34 | 2021-2025 | Fetroja |
| Boehringer Ingelheim Pharmaceuticals, INC. | $328.14 | 2019-2025 | Ofev |
| Mallinckrodt Hospital Products INC. | $212.65 | 2020-2022 | |
| Travere Therapeutics, INC. | $148.60 | 2022-2025 | Filspari |
| United Therapeutics Corporation | $144.05 | 2019-2025 | Tyvaso, Tyvaso |
| Janssen Pharmaceuticals, INC | $125.79 | 2020-2022 | |
| Verona Pharma, INC. | $114.81 | 2025 | Ohtuvayre |
| Genzyme Corporation | $109.61 | 2025 | |
| Advanced Respiratory, INC | $91.48 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $77.58 | 2025 | Dupixent |
| Merck Sharp & Dohme LLC | $70.73 | 2021-2025 | Winrevair |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $47.86 | 2021-2024 | Tavneos |
| Viatris Specialty LLC | $47.17 | 2025 | Yupelri |
| Inspire Medical Systems, INC. | $28.05 | 2024 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $25.72 | 2024 | |
| Gilead Sciences, INC. | $24.83 | 2021 | |
| Insmed, INC. | $21.64 | 2025 | Arikayce |
| Vifor Pharma, INC. | $20.90 | 2020 | |
| Roche Diagnostics Corporation | $19.27 | 2019 | |
| Philips North America LLC | $16.73 | 2024 | (Ak6) Vest Therapy |
| Baxter Healthcare | $15.47 | 2023 | Hillrom - Life 2000 Ventilation System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amelia Ng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.